Patents Assigned to Merck and Co., Inc.
  • Cyclohexapeptide compound
    Patent number: 5310873
    Abstract: A cyclohexapeptide base which is the nucleus of closely related antibiotics obtained by culturing Zalerion arboricola and its salts are described. They are useful intermediates for the preparation of new semisynthetic compounds having antimicrobial activity.
    Type: Grant
    Filed: March 12, 1990
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Dennis M. Schmatz, Jan S. Tkacz, Robert E. Schwartz, Mervyn Turner
  • O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
    Patent number: 5310901
    Abstract: O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylrapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inflammation, infectious diseases, the prevention of rejection of foreign organ transplants and the treatment of solid tumors.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
  • Cholesterol lowering compounds
    Patent number: 5310949
    Abstract: New Zaragozic acids have been isolated from a culture of MF5465. These compounds and their derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.
    Type: Grant
    Filed: September 2, 1992
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Claude Dufresne, Prakash S. Masurekar, Leslie A. Ferrell, Deborah L. Zink, Margaret S. Sosa
  • Benzo-fused lactams that promote the release of growth hormone
    Patent number: 5310737
    Abstract: There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused lactams as the active ingredient thereof are also disclosed.
    Type: Grant
    Filed: February 2, 1993
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Michael H. Fisher, William R. Schoen, Matthew J. Wyvratt, Robert J. DeVita
  • Process for preparing biphenyltetrazole compounds
    Patent number: 5310928
    Abstract: Method for the preparing biphenyltetrazole compounds which are angiotensin II receptor antagonists or which are useful intermediates to prepare angiotensin II receptor antagonists. An illustrative biphenyl tetrazole compound is 2-n-butyl-4-chloro-1-[(2'-(tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-im idazole-5-methanol, potassium salt.
    Type: Grant
    Filed: July 10, 1992
    Date of Patent: May 10, 1994
    Assignees: E. I. Du Pont de Nemours and Company, Merck & Co., Inc.
    Inventors: Young S. Lo, Lucius T. Rossano, Robert D. Larsen, Anthony O. King
  • Lipopeptide compounds
    Patent number: 5310726
    Abstract: Antifungal and antiparasital lipopeptide compounds stable in aqueous media are described. Stability in aqueous media render lipopeptides more useful for compositions for therapeutic applications.
    Type: Grant
    Filed: March 19, 1990
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventor: James M. Balkovec
  • Imidazolidyl rapamycin derivatives
    Patent number: 5310903
    Abstract: Imidazolidyl rapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inflammation, infectious diseases, the prevention of rejection of foreign organ transplants and the treatment of solid tumors.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, William H. Parsons, Matthew J. Wyvratt
  • Process for the preparation of 4-substituted-1,4-dihydropydrines
    Patent number: 5310917
    Abstract: 4-Substituted-1,4-dihydropyridines are prepared by a cycloaddition reaction in which the cyclization is driven to completion, after thermal reaction, by addition of an acid. Felodipine, a vasodilator, is prepared by a cycloaddition reaction of ethyl 3-aminocrotonate with a suitably substituted dichlorobenzylidine under reaction conditions whereby the product crystallizes out of the reaction solution and may be directly isolated by filtration.
    Type: Grant
    Filed: July 28, 1992
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventor: Joseph Auerbach
  • Varicella-zoster virus as a live recombinant vaccine
    Patent number: 5310668
    Abstract: A vaccine strain of varicella-zoster virus (VZV), tested in clinical trials, is capable of preventing chickenpox in children. This virus has been modified by the introduction into its genome of heterologous DNA which encodes an immunogenic polypeptide of another human pathogen. This heterologous polypeptide is expressed in cells infected by the recombinant virus. Such recombinant VZV is useful as a vaccine for chickenpox as well as for heterologous pathogens.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Elliott Kieff, Edward M. Scolnick, Robert S. Lowe
  • Inhibitors of HIV reverse transcriptase
    Patent number: 5308854
    Abstract: Novel aminopyridones inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: November 4, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Jacob M. Hoffman, Jr., Walfred S. Saari, Clarence S. Rooney, John S. Wai
  • Quinazolinones
    Patent number: 5308846
    Abstract: Substituted quinazolinones and pyridopyrimidines of structural formula 1 ##STR1## are angiotensin II antagonists useful in the treatment of disorders related to the renin-angiotensin system (RAS) such as hypertension, congestive heart failure, ocular hypertension and certain CNS disorders.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: May 3, 1994
    Assignees: Merck & Co., Inc., E. I. Du Pont de Nemours and Co.
    Inventors: Eric E. Allen, Richard E. Olson
  • Tricyclic derivatives of the thienodiazocine and thienothiadiazocine classes of compounds
    Patent number: 5308842
    Abstract: Conformationally constrained tricyclic derivatives of the thienodiazocine and thienothiadiazocine classes of compounds and ring homologs thereof are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and glaucoma associated therewith.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Substituted aromatic sulfonamides as antiglaucoma agents
    Patent number: 5308863
    Abstract: Thieno[2,3-b]thiopyran-2-sulfonamides and ring homologs with a hydrophilic substituted-alkyl group adjacent to the thiopyran sulfur are carbonic anhydrase inhibitors topically effective in lowering intraocular pressure.
    Type: Grant
    Filed: June 16, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Charles N. Habecker, Harold G. Selnick
  • Antibiotic agent
    Patent number: 5306708
    Abstract: A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H SEQ ID NO:1 or OH SEQ ID NO:2 and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.
    Type: Grant
    Filed: December 19, 1990
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Schwartz, David F. Sesin, Prakash S. Masurekar, Jerrold M. Liesch, Thomas C. Hallada, Otto D. Hensens
  • DNA encoding immunogenic gpIII glycoprotein of varicella-zoster virus
    Patent number: 5306635
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.
    Type: Grant
    Filed: June 9, 1992
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Paul M. Keller, Mark W. Riemen, Ronald W. Ellis, Andrew J. Davison, Robert S. Lowe
  • Methods of achieving antileukemia activity using 16-membered-macrolide-type compounds
    Patent number: 5306716
    Abstract: Inhibition of renal cancer, melanoma, colon cancer, lung cancer and leukemia cells by administration of compounds from the bafilomycin and hygrolidin groups of compounds.
    Type: Grant
    Filed: March 20, 1992
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Tom G. Holt, Richard L. Monaghan
  • Antibiotic producing microorganism
    Patent number: 5304485
    Abstract: An organism of the Sporormiella species produces a compound having the formula ##STR1## which is useful. The compound is useful as an antifungal agent.
    Type: Grant
    Filed: October 19, 1992
    Date of Patent: April 19, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Gerald F. Bills, Fernando Pelaez
  • Cholesterol lowering compounds produced by directed biosynthesis
    Patent number: 5302604
    Abstract: Compounds of Structural Formula (I) ##STR1## are produced by directed biosynthesis. These compounds are squalene synthetase inhibitors and thus useful as cholesterol lowering agents, antifungal agents and cancer treatment agents.
    Type: Grant
    Filed: October 6, 1992
    Date of Patent: April 12, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Kevin M. Byrne, Shieh-Shung T. Chen, Louis Kaplan, John G. MacConnell, Brian R. Petuch, Raymond F. White, Byron H. Arison
  • PHB-free gellan gum broth
    Patent number: 5300429
    Abstract: P. elodea mutants are produced which produce gellan gum broth which contains no detectable amount of poly-.beta.-hydroxy-butyrate (PHB).
    Type: Grant
    Filed: February 22, 1993
    Date of Patent: April 5, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John K. Baird, Joseph M. Cleary
  • Pharmaceutical tablet
    Patent number: D346442
    Type: Grant
    Filed: September 29, 1992
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth A. Kramer, Ashok V. Katadare